

FORWARDHEALTH
**PRIOR AUTHORIZATION / PREFERRED DRUG LIST (PA/PDL) FOR CYTOKINE AND CELL
ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR CROHN'S DISEASE**

Instructions: Type or print clearly. Before completing this form, read the Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Crohn's Disease Instructions, F-11305A. Providers may refer to the Forms page of the ForwardHealth Portal at www.forwardhealth.wi.gov/WIPortal/Content/provider/forms/index.htm.spage for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization/Preferred Drug List (PA/PDL) for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Crohn's Disease form signed by the prescriber before calling the Specialized Transmission Approval Technology-Prior Authorization (STAT-PA) system or submitting a PA request on the Portal or on paper. Providers may call Provider Services at (800) 947-9627 with questions.

SECTION I — MEMBER INFORMATION

1. Name — Member (Last, First, Middle Initial)

2. Member Identification Number

3. Date of Birth — Member

SECTION II — PRESCRIPTION INFORMATION

4. Drug Name

5. Drug Strength

6. Date Prescription Written

7. Directions for Use

8. Name — Prescriber

9. National Provider Identifier (NPI) — Prescriber

10. Address — Prescriber (Street, City, State, ZIP+4 Code)

11. Telephone Number — Prescriber

SECTION III — CLINICAL INFORMATION FOR CROHN'S DISEASE

12. Diagnosis Code and Description

13. Does the member have a diagnosis of Crohn's disease? Yes No

14. Does the member have moderate to severe symptoms of Crohn's disease? Yes No

15. Is the prescription written by a gastroenterologist or through a gastroenterology consultation? Yes No

Continued



DT-PA073-073

SECTION III — CLINICAL INFORMATION FOR CROHN'S DISEASE (Continued)

16. Has the member received **two** or more of the drugs listed below and taken each drug for at least **three** consecutive months and experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction? Yes No

If yes, check the boxes next to the drugs the member received. Indicate the dose of the drugs, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reactions, and the approximate dates the drugs were taken in the space provided.

- 1. 5-aminosalicylic (5-ASA) _____
- 2. 6-mercaptopurine (6MP) _____
- 3. azathioprine _____
- 4. corticosteroids _____
- 5. methotrexate _____
- 6. sulfasalazine _____

SECTION IIIA — ADDITIONAL CLINICAL INFORMATION FOR NON-PREFERRED CYTOKINE AND CAM ANTAGONIST DRUG REQUESTS

17. Has the member experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction to a preferred cytokine and CAM antagonist drug? Yes No

If yes, list the preferred cytokine and CAM antagonist drug and dose, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction, and the approximate dates the preferred cytokine and CAM antagonist drug was taken in the space provided.

SECTION IV — AUTHORIZED SIGNATURE

18. SIGNATURE — Prescriber	19. Date Signed
----------------------------	-----------------

SECTION V — FOR PHARMACY PROVIDERS USING STAT-PA

20. National Drug Code (11 digits)	21. Days' Supply Requested (Up to 365 Days)
------------------------------------	---

22. NPI

23. Date of Service (MM/DD/CCYY) (For STAT-PA requests, the date of service may be up to 31 days in the future and / or up to 14 days in the past.)

24. Place of Service

25. Assigned PA Number

26. Grant Date	27. Expiration Date	28. Number of Days Approved
----------------	---------------------	-----------------------------

SECTION VI — ADDITIONAL INFORMATION

29. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the product requested may be included here.